Dianthus Therapeutics, Inc. /DE/
About Dianthus Therapeutics, Inc. /DE/
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $2.0M
- Net income
- -$162.3M
- Total assets
- $530.9M
- Market cap
- $4.4B
- Operating margin
- -8739.3%
- Net margin
- -7973.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.0M
- Operating expenses
- $180.0M
- Operating income
- -$177.9M
- Income tax
- $0
- Net income
- -$162.3M
- EPS (basic)
- $-4.20
- EPS (diluted)
- $-4.20
Balance sheet
- Total assets
- $530.9M
- Current assets
- $409.4M
- Total liabilities
- $37.5M
- Current liabilities
- $30.7M
- Shareholders’ equity
- $493.4M
Cash flow
- Operating cash flow
- -$129.1M
- Investing cash flow
- -$122.8M
- Financing cash flow
- $280.1M
- Net cash flow
- $28.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $4.4B
- EPS (diluted)
- $-4.2
- Shares outstanding
- 57.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 12, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $162.3M in FY2025.
- Revenue declined 28% from FY2023 to FY2025.
- Trading 20% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Dianthus Therapeutics, Inc. /DE/.
Write a review
News about Dianthus Therapeutics, Inc. /DE/
News & sentiment via Polygon.io
